Last reviewed · How we verify
Montelukast (drug)
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction.
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction. Used for Asthma (chronic maintenance and acute treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.
At a glance
| Generic name | Montelukast (drug) |
|---|---|
| Sponsor | Firestone Institute for Respiratory Health |
| Drug class | Cysteinyl leukotriene receptor antagonist (LTRA) |
| Target | CysLT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Immunology |
| Phase | FDA-approved |
Mechanism of action
Leukotrienes are inflammatory mediators released by mast cells and eosinophils that bind to CysLT1 receptors, causing airway smooth muscle contraction, mucus secretion, and eosinophil recruitment. By antagonizing these receptors, montelukast reduces airway inflammation and improves airflow in asthma and allergic rhinitis. This mechanism is particularly effective in aspirin-exacerbated respiratory disease and exercise-induced asthma.
Approved indications
- Asthma (chronic maintenance and acute treatment)
- Allergic rhinitis
- Exercise-induced bronchoconstriction
- Aspirin-exacerbated respiratory disease
Common side effects
- Headache
- Influenza-like illness
- Abdominal pain
- Cough
- Neuropsychiatric effects (agitation, anxiety, depression, suicidal ideation)
Key clinical trials
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- Premedication to Reduce Amivantamab Associated Infusion Related Reactions (PHASE2)
- Montelukast in Parkinson Disease (PHASE2, PHASE3)
- Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (PHASE2)
- Daratumumab in STK11 Mutated NSCLC (PHASE2)
- Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer (NA)
- PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia (PHASE1, PHASE2)
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Montelukast (drug) CI brief — competitive landscape report
- Montelukast (drug) updates RSS · CI watch RSS
- Firestone Institute for Respiratory Health portfolio CI